MHC Class I Stability is Modulated by Cell Surface Sialylation in Human Dendritic Cells.

cancer-vaccines dendritic-cells, antigen-presentation, MHC-I, immunogenicity, T-cell response

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
10 Mar 2020
Historique:
received: 15 01 2020
revised: 04 03 2020
accepted: 06 03 2020
entrez: 14 3 2020
pubmed: 14 3 2020
medline: 14 3 2020
Statut: epublish

Résumé

Maturation of human Dendritic Cells (DCs) is characterized by increased expression of antigen presentation molecules, and overall decreased levels of sialic acid at cell surface. Here, we aimed to identify sialylated proteins at DC surface and comprehend their role and modulation. Mass spectrometry analysis of DC's proteins, pulled down by a sialic acid binding lectin, identified molecules of the major human histocompatibility complex class I (MHC-I), known as human leucocyte antigen (HLA). After desialylation, DCs showed significantly higher reactivity with antibodies specific for properly folded MHC-I-β2-microglobulin complex and for β2-microglobulin but showed significant lower reactivity with an antibody specific for free MHC-I heavy chain. Similar results for antibody reactivities were observed for TAP2-deficient lymphoblastoid T2 cells, which express HLA-A*02:01. Using fluorescent peptide specifically fitting the groove of HLA-A*02:01, instead of antibody staining, also showed higher peptide binding on desialylated cells, confirming higher surface expression of MHC-I complex. A decay assay showed that desialylation doubled the half-life of MHC-I molecules at cell surface in both DCs and T2 cells. The biological impact of DC´s desialylation was evaluated in co-cultures with autologous T cells, showing higher number and earlier immunological synapses, and consequent significantly increased production of IFN-γ by T cells. In summary, sialic acid content modulates the expression and stability of complex MHC-I, which may account for the improved DC-T synapses.

Identifiants

pubmed: 32164343
pii: pharmaceutics12030249
doi: 10.3390/pharmaceutics12030249
pmc: PMC7150992
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Ministério da Ciência, Tecnologia e Ensino Superior
ID : PD/BD/52472/2014;
Organisme : Ministério da Ciência, Tecnologia e Ensino Superior
ID : CEECIND/03186/2017
Organisme : Horizon 2020
ID : GlyCoCan programme; grant agreement number 676421
Organisme : FCT/MCTES (UID/Multi/04378/2013)
ID : POCI-01-0145-FEDER-007728

Références

Mol Oncol. 2014 May;8(3):753-65
pubmed: 24656965
Int J Cancer. 1999 Aug 27;82(5):669-77
pubmed: 10417764
J Immunol. 1996 May 15;156(10):3755-64
pubmed: 8621911
Science. 1991 Dec 20;254(5039):1788-91
pubmed: 1763329
Cell. 1978 May;14(1):9-20
pubmed: 667938
Cell Signal. 2010 Feb;22(2):314-24
pubmed: 19796680
Immunol Lett. 2010 Jun 15;131(1):89-96
pubmed: 20206207
J Immunol. 1986 Oct 1;137(7):2299-306
pubmed: 3760563
J Clin Immunol. 1999 Jan;19(1):12-25
pubmed: 10080101
J Proteome Res. 2019 Mar 1;18(3):1125-1132
pubmed: 30582698
Eur J Immunol. 1979 Jul;9(7):536-45
pubmed: 91522
Immunol Rev. 1979;47:3-61
pubmed: 95015
Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):13944-9
pubmed: 10570178
Adv Immunol. 1997;64:105-37
pubmed: 9100981
J Leukoc Biol. 2011 Aug;90(2):313-21
pubmed: 21551251
Anal Chem. 2011 Sep 15;83(18):7035-43
pubmed: 21809823
J Immunol. 2014 Nov 15;193(10):4803-13
pubmed: 25311806
J Virol. 2004 Feb;78(3):1525-39
pubmed: 14722307
Cell. 1999 Oct 1;99(1):23-33
pubmed: 10520991
J Proteomics. 2018 Jan 16;171:95-106
pubmed: 28782717
Front Immunol. 2015 Jul 02;6:335
pubmed: 26191062
Nucleic Acids Res. 2008 Jul 1;36(Web Server issue):W509-12
pubmed: 18463140
J Virol. 1988 Jun;62(6):1974-80
pubmed: 2835502
Semin Immunopathol. 2012 May;34(3):425-41
pubmed: 22461020
Mol Biol Cell. 2004 Aug;15(8):3542-52
pubmed: 15146059
J Biol Chem. 2006 Apr 28;281(17):11805-14
pubmed: 16484231
Oncotarget. 2016 Jul 5;7(27):41053-41066
pubmed: 27203391
Lancet Oncol. 2014 Jun;15(7):e257-67
pubmed: 24872109
J Immunol. 1979 Jul;123(1):342-9
pubmed: 87477
Trends Immunol. 2017 Aug;38(8):577-593
pubmed: 28610825
Clin Cancer Res. 2016 Apr 15;22(8):1897-906
pubmed: 27084743
Blood. 2007 Oct 15;110(8):2872-9
pubmed: 17585053
Bioinformatics. 2016 Feb 15;32(4):511-7
pubmed: 26515819
Immunity. 1998 Jan;8(1):89-95
pubmed: 9462514
Immunology. 1999 Jun;97(2):287-93
pubmed: 10447744
Nature. 1993 Jan 28;361(6410):359-62
pubmed: 7678924
Ann N Y Acad Sci. 2012 Apr;1253:16-36
pubmed: 22524423
J Immunol. 2007 Dec 15;179(12):8216-24
pubmed: 18056365
J Cell Biol. 1992 Jul;118(2):267-83
pubmed: 1629235
Glycoconj J. 2008 Apr;25(3):259-68
pubmed: 18080182
Nature. 1990 Aug 16;346(6285):655-7
pubmed: 2166918
Immunology. 2009 Sep;128(1 Suppl):e621-31
pubmed: 19740323
Nature. 1987 Oct 8-14;329(6139):506-12
pubmed: 3309677
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
J Immunol. 2003 Apr 15;170(8):4178-88
pubmed: 12682250
Genomics Proteomics Bioinformatics. 2013 Apr;11(2):96-104
pubmed: 23459159
Annu Rev Immunol. 2000;18:767-811
pubmed: 10837075
J Immunol. 2005 Aug 1;175(3):1373-81
pubmed: 16034072
Front Immunol. 2012 Feb 28;3:31
pubmed: 22566915
Glycoconj J. 2009 Dec;26(9):1197-212
pubmed: 19430901
J Biol Chem. 2014 Mar 7;289(10):7178-89
pubmed: 24425878
Cell. 2001 Aug 10;106(3):255-8
pubmed: 11509172
EMBO J. 2013 May 15;32(10):1478-88
pubmed: 23584533
Microbes Infect. 2012 Sep;14(11):894-903
pubmed: 22580092
J Cell Biol. 1991 Feb;112(4):579-88
pubmed: 1993732
Nature. 1995 May 11;375(6527):148-51
pubmed: 7753171
Immunol Rev. 2016 Jul;272(1):65-79
pubmed: 27319343

Auteurs

Zélia Silva (Z)

UCIBIO, Departamento Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, 2829-516 Caparica,Portugal.

Tiago Ferro (T)

UCIBIO, Departamento Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, 2829-516 Caparica,Portugal.
CDG & Allies - PPAIN- Congenital Disorders of Glycosylation & Allies - Professionals and Patient Associations International Network, 2829-516 Caparica,Portugal.

Danielle Almeida (D)

UCIBIO, Departamento Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, 2829-516 Caparica,Portugal.

Helena Soares (H)

Human Immunobiology and Pathogenesis, CEDOC-Chronic Diseases Research Centre, NOVA Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, 1150-082 Lisbon, Portugal.

José Alexandre Ferreira (JA)

Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, 4200-162 Porto, Portugal.
Porto Comprehensive Cancer Center (P.ccc), 4200-072 Porto, Portugal.

Fanny M Deschepper (FM)

UCIBIO, Departamento Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, 2829-516 Caparica,Portugal.

Paul J Hensbergen (PJ)

Center for Proteomics and Metabolomics, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.

Martina Pirro (M)

Center for Proteomics and Metabolomics, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.

Sandra J van Vliet (SJ)

Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Molecular Cell Biology and Immunology, Cancer Center Amsterdam, Amsterdam Infection and Immunity Institute, De Boelelaan 1117, 1081 HzAmsterdam, The Netherlands.

Sebastian Springer (S)

Department of Life Sciences and Chemistry, Jacobs University, 28759 Bremen, Germany.

Paula A Videira (PA)

UCIBIO, Departamento Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, 2829-516 Caparica,Portugal.
CDG & Allies - PPAIN- Congenital Disorders of Glycosylation & Allies - Professionals and Patient Associations International Network, 2829-516 Caparica,Portugal.

Classifications MeSH